Highlights
Predicting Hidden Risk
Nodal negativity does not equate to a cure; over 10% of patients with lymph node-negative (LN-negative) pancreatic neuroendocrine tumors (PanNETs) experience recurrence within ten years.
The 13-Point Risk Score
A novel scoring system using male sex, tumor size, WHO grade, and lymphovascular invasion (LVI) effectively stratifies patients into low, moderate, and high risk for recurrence.
Genomic Insights
Recurrent tumors are characterized by higher mutational burdens and specific alterations in genes such as MTOR and DAXX, providing a biological basis for aggressive behavior in seemingly localized disease.
Background: The False Security of Nodal Negativity
In the management of localized pancreatic neuroendocrine tumors (PanNETs), lymph node (LN) metastasis has long been regarded as the premier predictor of poor outcomes. Consequently, patients who undergo pancreatectomy and are found to have negative lymph nodes are often considered to be at low risk for systemic relapse. However, clinical reality frequently contradicts this assumption. A significant portion of LN-negative patients still face tumor recurrence, leading to uncertainty regarding the optimal frequency and duration of postoperative surveillance.
Traditional staging systems often fail to capture the biological heterogeneity of PanNETs. While the absence of nodal involvement is favorable, it does not account for micro-metastatic spread or aggressive molecular phenotypes. There has been a pressing clinical need for a validated tool that integrates clinical, pathological, and genomic data to guide risk-adapted surveillance and potentially identify candidates for adjuvant therapeutic strategies.
Study Design and Methodology
To address this gap, Ventin et al. conducted a comprehensive retrospective case-control study involving five high-volume academic institutions in the United States between 2000 and 2023. The study specifically targeted patients with localized PanNETs who underwent surgical resection.
To ensure the accuracy of the LN-negative status and avoid the pitfalls of understaging (stage migration), the researchers set a strict inclusion criterion: at least 8 lymph nodes had to be evaluated and found negative. Out of 2024 patients initially screened, 770 met these rigorous criteria. The cohort had a median follow-up of 50.6 months. The primary endpoint was tumor recurrence, and independent predictors were identified through multivariable logistic regression to construct a composite 13-point risk score. Performance was validated both internally and through an external cohort that included genomic profiling.
Key Findings: Constructing the Risk Profile
Independent Predictors of Recurrence
The study identified four key factors that independently predicted recurrence in LN-negative patients:
1. Male Sex (Odds Ratio [OR], 2.2)
2. Tumor Size 3 cm or larger (OR, 2.64)
3. World Health Organization (WHO) Grade 2 or higher (OR, 3.70)
4. Presence of Lymphovascular Invasion (OR, 3.84)
The 13-Point Scoring System
Using these variables, the researchers developed a point-based system. Patients were stratified into three distinct risk categories:
– Low Risk (0–4 points): Recurrence rate of 2.4%
– Moderate Risk (5–8 points): Recurrence rate of 9.0%
– High Risk (9–13 points): Recurrence rate of 27.7%
Survival Outcomes
The disparity in survival was striking. The 10-year disease-free survival (DFS) rates were 96.1% for the low-risk group, 83.6% for the moderate-risk group, and only 51.3% for the high-risk group. These findings suggest that high-risk LN-negative patients exhibit a clinical course more akin to those with nodal metastases.
The Genomic Landscape of Recurrent PanNETs
One of the most significant aspects of this research was the inclusion of genomic profiling in an external validation cohort. The researchers sought to determine if the clinical risk score correlated with underlying biological drivers.
Recurrent tumors demonstrated a higher tumor mutational burden (TMB) and an increased count of somatic mutations. Specifically, mutations were identified in genes involved in key oncogenic pathways, including MTOR (growth signaling), DAXX (chromatin remodeling and telomere maintenance), and CDC42BPB. The presence of these mutations validates the clinical risk score, suggesting that the clinical factors (like size and grade) are outward manifestations of an aggressive internal genomic profile.
Expert Commentary and Clinical Implications
The implications of this study for clinical practice are profound. Currently, many postoperative surveillance guidelines for PanNETs are one-size-fits-all or based heavily on simple TNM staging. This study provides a framework for “precision surveillance.”
For patients in the high-risk LN-negative group, clinicians should consider more intensive imaging schedules (e.g., every 6 months rather than annually) and perhaps extend the duration of follow-up beyond the standard 5 to 10 years, as recurrences in PanNETs can occur late. Furthermore, this high-risk subgroup represents the ideal population for future clinical trials investigating adjuvant therapies, such as somatostatin analogs or targeted inhibitors like everolimus.
However, limitations must be noted. As a retrospective study spanning two decades, changes in imaging sensitivity and surgical techniques may introduce bias. Additionally, while the 8-node threshold increases staging confidence, it may limit the generalizability to centers where such extensive lymphadenectomy is not routine. Nevertheless, the high C-statistic (0.95 in external validation) underscores the robustness of the model.
Summary
The study by Ventin et al. challenges the notion that negative lymph nodes guarantee a low risk of recurrence in pancreatic neuroendocrine tumors. By integrating sex, tumor size, grade, and lymphovascular invasion into a validated 13-point score, clinicians can now identify a subset of patients who require heightened vigilance. Coupled with genomic evidence of MTOR and DAXX mutations, this risk score moves the field closer to personalized management for PanNET patients, ensuring that high-risk individuals receive the attention they need while low-risk individuals may be spared unnecessary anxiety and over-testing.
References
1. Ventin M, Arya S, Zhang L, et al. Recurrence in Patients With Lymph Node-Negative Pancreatic Neuroendocrine Tumors. JAMA Surg. 2025;e255401. doi:10.1001/jamasurg.2025.5401.
2. Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557-577.
3. Jilesen AP, van Eijck CH, Busch OR, et al. Postoperative surveillance in patients with pancreatic neuroendocrine tumors. World J Surg. 2016;40(4):852-861.